{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T09:10:05Z","timestamp":1758964205004,"version":"3.44.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.clinthera.2020.09.014","type":"journal-article","created":{"date-parts":[[2020,11,5]],"date-time":"2020-11-05T07:03:37Z","timestamp":1604559817000},"page":"2136-2147.e3","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Treatment Patterns and Relapses Among Newly Treated Multiple Sclerosis Patients From a Retrospective Claims Analysis"],"prefix":"10.1016","volume":"42","author":[{"given":"Daniel","family":"Kantor","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rina","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3562-5145","authenticated-orcid":false,"given":"Corey","family":"Pelletier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Tian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Virginia","family":"Noxon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara H.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Machaon","family":"Bonafede","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2020.09.014_bib1","doi-asserted-by":"crossref","first-page":"e1029","DOI":"10.1212\/WNL.0000000000007035","article-title":"The prevalence of MS in the United States: a population-based estimate using health claims data","volume":"92","author":"Wallin","year":"2019","journal-title":"Neurology"},{"issue":"6 Suppl","key":"10.1016\/j.clinthera.2020.09.014_bib2","first-page":"s141","article-title":"Overview and diagnosis of multiple sclerosis","volume":"22","author":"Hunter","year":"2016","journal-title":"Am J Manag Care"},{"issue":"2 Suppl","key":"10.1016\/j.clinthera.2020.09.014_bib3","first-page":"S15","article-title":"Overview of the epidemiology, diagnosis, and disease progression associated with multiple sclerosis","volume":"19","author":"Tullman","year":"2013","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.clinthera.2020.09.014_bib4","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.clinthera.2020.09.014_bib5","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1212\/WNL.0000000000000560","article-title":"Defining the clinical course of multiple sclerosis: the 2013 revisions","volume":"83","author":"Lublin","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.clinthera.2020.09.014_bib6","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a028928","article-title":"Clinical course of multiple sclerosis","volume":"8","author":"Klineova","year":"2018","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.clinthera.2020.09.014_bib7","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1212\/WNL.0b013e3181e3973f","article-title":"New perspectives in the natural history of multiple sclerosis","volume":"74","author":"Tremlett","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.clinthera.2020.09.014_bib8","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1002\/ana.24747","article-title":"Long-term evolution of multiple sclerosis disability in the treatment era","volume":"80","author":"Cree","year":"2016","journal-title":"Ann Neurol"},{"issue":"Pt 7","key":"10.1016\/j.clinthera.2020.09.014_bib9","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1093\/brain\/awq118","article-title":"The natural history of multiple sclerosis: a geographically based study 10: relapses and long-term disability","volume":"133","author":"Scalfari","year":"2010","journal-title":"Brain"},{"key":"10.1016\/j.clinthera.2020.09.014_bib10","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1212\/01.WNL.0000096175.39831.21","article-title":"Effect of relapses on development of residual deficit in multiple sclerosis","volume":"61","author":"Lublin","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.clinthera.2020.09.014_bib11","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1111\/joim.12203","article-title":"Established and novel disease-modifying treatments in multiple sclerosis","volume":"275","author":"Cross","year":"2014","journal-title":"J\u00a0Intern Med"},{"key":"10.1016\/j.clinthera.2020.09.014_bib12","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1212\/WNL.0000000000005345","article-title":"Comprehensive systematic review summary: disease-modifying therapies for adults with multiple sclerosis","volume":"90","author":"Rae-Grant","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.clinthera.2020.09.014_bib13","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1159\/000382130","article-title":"Multiple sclerosis relapses: epidemiology, outcomes and management. A systematic review","volume":"44","author":"Kalincik","year":"2015","journal-title":"Neuroepidemiology"},{"key":"10.1016\/j.clinthera.2020.09.014_bib14","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s40263-017-0412-5","article-title":"Outcome measures in clinical trials for multiple sclerosis","volume":"31","author":"van Munster","year":"2017","journal-title":"CNS Drugs"},{"key":"10.1016\/j.clinthera.2020.09.014_bib15","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1212\/WNL.0000000000005347","article-title":"Practice guideline recommendations summary: disease-modifying therapies for adults with multiple sclerosis: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology","volume":"90","author":"Rae-Grant","year":"2018","journal-title":"Neurology"},{"year":"2019","series-title":"The Use of Disease Modifying Therapies in Multiple Sclerosis: Principles and Current Evidence: Multiple Sclerosis Coalition","author":"Costello","key":"10.1016\/j.clinthera.2020.09.014_bib16"},{"key":"10.1016\/j.clinthera.2020.09.014_bib17","first-page":"254","article-title":"Improving multiple sclerosis care: an analysis of the necessity for medication therapy management services among the patient population","volume":"20","author":"Anderson","year":"2014","journal-title":"J\u00a0Manag Care Spec Pharm"},{"key":"10.1016\/j.clinthera.2020.09.014_bib18","doi-asserted-by":"crossref","first-page":"55","DOI":"10.2147\/PPA.S118107","article-title":"An evaluation of adherence in patients with multiple sclerosis newly initiating treatment with a self-injectable or an oral disease-modifying drug","volume":"11","author":"Munsell","year":"2017","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.clinthera.2020.09.014_bib19","first-page":"601","article-title":"Impact of medication adherence to disease-modifying drugs on severe relapse, and direct and indirect costs among employees with multiple sclerosis in the US","volume":"15","author":"Ivanova","year":"2012","journal-title":"J\u00a0Med Econ"},{"key":"10.1016\/j.clinthera.2020.09.014_bib20","first-page":"844","article-title":"Real-world adherence and persistence to oral disease-modifying therapies in multiple sclerosis patients over 1 year","volume":"23","author":"Johnson","year":"2017","journal-title":"J\u00a0Manag Care Spec Pharm"},{"key":"10.1016\/j.clinthera.2020.09.014_bib21","article-title":"Assessment of treatment patterns associated with injectable disease-modifying therapy among relapsing-remitting multiple sclerosis patients","volume":"3","author":"Nicholas","year":"2017","journal-title":"Mult Scler J Exp Transl Clin"},{"key":"10.1016\/j.clinthera.2020.09.014_bib22","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1016\/j.clinthera.2013.07.330","article-title":"Treatment patterns in disease-modifying therapy for patients with multiple sclerosis in the United States","volume":"35","author":"Bonafede","year":"2013","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2020.09.014_bib23","first-page":"618","article-title":"Medical chart validation of an algorithm for identifying multiple sclerosis relapse in healthcare claims","volume":"13","author":"Chastek","year":"2010","journal-title":"J\u00a0Med Econ"},{"key":"10.1016\/j.clinthera.2020.09.014_bib24","first-page":"280","article-title":"Contribution of relapses to disability in multiple sclerosis","volume":"255","author":"Hirst","year":"2008","journal-title":"J\u00a0Neurol"},{"key":"10.1016\/j.clinthera.2020.09.014_bib25","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0054756","article-title":"Impact of mobility impairment on indirect costs and health-related quality of life in multiple sclerosis","volume":"8","author":"Coleman","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.clinthera.2020.09.014_bib26","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1186\/s12913-016-1532-1","article-title":"Quantifying the relationship between increased disability and health care resource utilization, quality of life, work productivity, health care costs in patients with multiple sclerosis in the US","volume":"16","author":"Jones","year":"2016","journal-title":"BMC Health Serv Res"},{"key":"10.1016\/j.clinthera.2020.09.014_bib27","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jns.2013.04.007","article-title":"Direct and indirect cost burden associated with multiple sclerosis relapses: excess costs of persons with MS and their spouse caregivers","volume":"330","author":"Parise","year":"2013","journal-title":"J\u00a0Neurol Sci"},{"key":"10.1016\/j.clinthera.2020.09.014_bib28","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.msard.2015.03.005","article-title":"Impact of multiple sclerosis relapse: the NARCOMS participant perspective","volume":"4","author":"Nickerson","year":"2015","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.clinthera.2020.09.014_bib29","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.msard.2014.09.002","article-title":"Economic costs associated with an MS relapse","volume":"3","author":"O'Connell","year":"2014","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.clinthera.2020.09.014_bib30","doi-asserted-by":"crossref","first-page":"251","DOI":"10.2147\/CEOR.S130334","article-title":"Adherence to disease-modifying therapies and its impact on relapse, health resource utilization, and costs among patients with multiple sclerosis","volume":"9","author":"Burks","year":"2017","journal-title":"Clinicoecon Outcomes Res"},{"key":"10.1016\/j.clinthera.2020.09.014_bib31","first-page":"711","article-title":"Impact of increasing adherence to disease-modifying therapies on healthcare resource utilization and direct medical and indirect work loss costs for patients with multiple sclerosis","volume":"18","author":"Yermakov","year":"2015","journal-title":"J\u00a0Med Econ"},{"key":"10.1016\/j.clinthera.2020.09.014_bib32","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.msard.2016.06.001","article-title":"Comparative efficacy of disease-modifying therapies for patients with relapsing remitting multiple sclerosis: systematic review and network meta-analysis","volume":"9","author":"Fogarty","year":"2016","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.clinthera.2020.09.014_bib33","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1017\/cjn.2018.17","article-title":"Managing multiple sclerosis: treatment initiation, modification, and sequencing","volume":"45","author":"Freedman","year":"2018","journal-title":"Can J Neurol Sci"},{"key":"10.1016\/j.clinthera.2020.09.014_bib34","first-page":"2351","article-title":"The sequence of disease-modifying therapies in relapsing multiple sclerosis: safety and immunologic considerations","volume":"264","author":"Pardo","year":"2017","journal-title":"J\u00a0Neurol"},{"key":"10.1016\/j.clinthera.2020.09.014_bib35","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1177\/1756285614555335","article-title":"Patient preferences for disease-modifying drugs in multiple sclerosis therapy: a choice-based conjoint analysis","volume":"7","author":"Utz","year":"2014","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1016\/j.clinthera.2020.09.014_bib36","doi-asserted-by":"crossref","first-page":"74","DOI":"10.7224\/1537-2073.2013-053","article-title":"Patient preferences for attributes of multiple sclerosis disease-modifying therapies: development and results of a ratings-based conjoint analysis","volume":"17","author":"Wilson","year":"2015","journal-title":"Int J MS Care"},{"year":"2020","series-title":"Tecfidera [package insert]","key":"10.1016\/j.clinthera.2020.09.014_bib37"},{"year":"2019","series-title":"Plegridy [package insert]","key":"10.1016\/j.clinthera.2020.09.014_bib38"},{"year":"2020","series-title":"Ocrevus [package insert]","key":"10.1016\/j.clinthera.2020.09.014_bib39"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291820304641?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291820304641?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T08:53:38Z","timestamp":1758963218000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291820304641"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":39,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["S0149291820304641"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2020.09.014","relation":{},"ISSN":["0149-2918"],"issn-type":[{"type":"print","value":"0149-2918"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment Patterns and Relapses Among Newly Treated Multiple Sclerosis Patients From a Retrospective Claims Analysis","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2020.09.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}